Guy Lebeau is Company Group Chairman for the Cordis Franchise, a Johnson & Johnson company.

Dr. Guy Lebeau was recently appointed worldwide president of Cordis Corporation, overseeing the company's cardiovascular, endovascular, neurovascular and electrophysiology business units, which together account for one of Johnson & Johnson's most promising franchises today. He joined Ethicon, Inc., a Johnson & Johnson company, in March 1991 as a research & development assistant. He then moved to Ethicon Endo-Surgery, Inc. where he held positions of increased responsibility in Sales & Marketing, leading to the appointment of Vice President of International Development.

Dr. Lebeau was later named International President for Biosense Webster, Inc. where he led the merger of Biosense, Ltd and Webster, Inc. He became Worldwide President in 2001 and focused the company on the development of therapy for Atrial Fibrillation. In 2002, in addition to his responsibilities for Biosense Webster, Dr. Lebeau was in charge of the development of Cordis Neurovascular, Inc. where he developed a mid-term strategy for the treatment of aneurysm and long-term plan for approaching the treatment of stroke.

Prior to joining Ethicon, Dr. Lebeau was Assistant Professor of Surgery Rennes (France) University School of Medicine, Digestive Surgery Department Organ Transplant Unit. He was also Associate Researcher in the National Science Institute for Medical Research.

A graduate of the University of Rennes (France) and Paris (France), he obtained Master's Degrees in Cellular Biology and Transplant Immunology. His post-graduate fellowship training in Organ Transplant was at the University Hospital of Pittsburgh in Dr. T.E. Starzl's department. Certified in General Surgery, Dr. Lebeau has authored journal articles and book chapters in the fields of hepathology, liver transplant and general surgery.